CX Institutional’s BioMarin Pharmaceuticals BMRN Stock Holding History

CX Institutional’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$20K	Buy	325 +91	+39%	+$5.73K	﹤0.01%	1223
2026 Q2	$13K	Sell	234 -54	-19%	-$2.96K	﹤0.01%	1249
2026 Q1	$16K	Buy	288 +260	+929%	+$15.2K	﹤0.01%	1176
2025 Q4	$2K	Buy	+28	New	+$1.52K	﹤0.01%	1351
2021 Q4	–	Sell	-10	Closed	-$1K	–	399
2021 Q3	$1K	Hold	10	–	–	﹤0.01%	930
2021 Q2	$1K	Buy	+10	New	+$793	﹤0.01%	929
2021 Q1	–	Sell	-17	Closed	-$1K	–	870
2020 Q4	$1K	Sell	17 -3	-15%	-$238	﹤0.01%	841
2020 Q3	$2K	Buy	+20	New	+$2.02K	﹤0.01%	800
2019 Q3	–	Sell	-27	Closed	-$2K	–	805
2019 Q2	$2K	Sell	27 -24	-47%	-$2.05K	﹤0.01%	743
2019 Q1	$5K	Buy	+51	New	+$4.73K	﹤0.01%	539

Other funds holding BMRN

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Fort Washington Investment Advisors Cincinnati, Ohio $19.7B AUM 20.11% 1-Year Est. Return

Covea Finance Paris, France $3.07B AUM 27.46% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $83.2B AUM 35.34% 1-Year Est. Return

KBC Group Brussels, Belgium $47.9B AUM 37.61% 1-Year Est. Return

Mutual of America Capital Management New York $10.1B AUM 33.74% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $52.9B AUM 36.03% 1-Year Est. Return

Amalgamated Bank New York $14.3B AUM 35.81% 1-Year Est. Return

Apollon Wealth Management Mount Pleasant, South Carolina $8.72B AUM 23.07% 1-Year Est. Return

Secure Asset Management Troy, Michigan $753M AUM 20.9% 1-Year Est. Return

CX Institutional's BMRN Position: Q3 2026 in Review

CX Institutional increased its BioMarin Pharmaceuticals (BMRN) stake by 39% in Q3 2026, buying an estimated $5.73K and bringing the position to 325 shares worth $20K. The position accounts for ﹤0.01% of the portfolio, ranked #1223.

CX Institutional first reported a position in BMRN in Q1 2019 and has held it in 10 quarters since. 97 funds tracked by Wall St. Rank hold BMRN as of Q3 2026.

CX Institutional held 325 shares of BioMarin Pharmaceuticals worth $20K as of Q3 2026.
CX Institutional bought 91 BioMarin Pharmaceuticals shares in Q3 2026, an estimated $5.73K.
BioMarin Pharmaceuticals made up ﹤0.01% of CX Institutional's portfolio in Q3 2026, its #1223 holding.
CX Institutional first reported a position in BioMarin Pharmaceuticals in Q1 2019 and has held it in 10 quarters since.
97 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2026.

Based on CX Institutional's 13F filing for Q3 2026, filed 2 Oct 2026.